Chimeric anti-CD20 monoclonal antibody that depletes B cells via complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and induction of apoptosis.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on B cells and depletes CD20-positive cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and induction of apoptosis.
YES
DIRECT
Binding to CD20 triggers complement-dependent cytotoxicity and Fc-mediated ADCC by immune effectors, and can directly induce apoptosis of CD20+ B cells.
Gene-modified cellular immunotherapy consisting of gamma-delta T lymphocytes engineered to express a CD19-specific chimeric antigen receptor; administered by IV infusion to deplete CD19+ B-lineage cells and suppress B cell–mediated autoimmunity.
Gamma-delta T lymphocytes engineered to express a CD19-specific chimeric antigen receptor bind CD19 on B-lineage cells, triggering T-cell activation and cytotoxicity (perforin/granzyme and inflammatory cytokines) to deplete CD19+ B cells and suppress B cell–mediated autoimmunity.
YES
DIRECT
CD19 CAR γδ T cells bind CD19 on target cells, become activated, and kill via perforin/granzyme-mediated cytolysis (with supportive inflammatory cytokines).
Antibody-drug conjugate targeting Trop-2; a humanized anti–Trop-2 monoclonal antibody linked to SN-38 (topoisomerase I inhibitor) to deliver cytotoxic payload to Trop-2–expressing tumor cells, causing DNA damage and bystander killing.
Humanized anti–Trop-2 monoclonal antibody conjugated to SN-38 (topoisomerase I inhibitor). After binding Trop-2 on tumor cells and internalization, the linker is cleaved to release SN-38, which stabilizes topo I–DNA complexes, causing DNA strand breaks, cell-cycle arrest, and apoptosis; the membrane-permeable payload can also produce bystander killing.
YES
INDIRECT
The ADC targets Trop-2 for delivery; once internalized, the SN-38 payload inhibits DNA topoisomerase I, causing DNA damage, cell-cycle arrest, and apoptosis (with possible bystander killing).
A fully human type I anti-CD20 monoclonal antibody administered subcutaneously that depletes CD20+ B cells via complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity, reducing B-cell antigen presentation and autoantibody production in multiple sclerosis.
Fully human type I anti-CD20 monoclonal antibody that binds CD20 on B lymphocytes and depletes them via complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity, reducing B-cell antigen presentation and autoantibody production.
YES
DIRECT
Binds CD20 on B cells and induces complement-dependent cytotoxicity and Fc-mediated effector killing (ADCC/ADCP), leading to lysis/depletion of CD20+ cells.
Humanized IgG1 monoclonal antibody targeting MUC1 on cancer cells; engages Fcγ receptor–bearing effector cells (e.g., NK cells/macrophages) to mediate ADCC/CDC.
Humanized IgG1 monoclonal antibody targeting MUC1 on tumor cells; engages Fcγ receptor–bearing effector cells (e.g., NK cells, macrophages) to induce antibody‑dependent cellular cytotoxicity and complement‑dependent cytotoxicity, resulting in tumor cell killing.
YES
DIRECT
Antibody binds MUC1 on tumor cells and engages FcγR-bearing effector cells to mediate ADCC and activates complement for CDC, leading to lysis of MUC1-expressing cells.